S. 1322 — Introduced in Senate

II 113th CONGRESS 1st Session S. 1322 IN THE SENATE OF THE UNITED STATES July 18, 2013 Ms. Klobuchar (for herself, Mr. Graham, and Mrs. Feinstein) introduced the following bill; which was read twice and referred to the Committee on the Judiciary A BILL To amend the Controlled Substances Act relating to controlled substance analogues. 1. Short title This Act may be cited as the Synthetic Abuse and Labeling of Toxic Substances Act of 2013 or the SALTS Act. 2. Controlled substance analogues Section 203 of the Controlled Substances Act (21 U.S.C. 813) is amended— (1) by striking A controlled and inserting (a) In general.—A controlled; and (2) by adding at the end the following: (b) Determination In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors: (1) The marketing, advertising, and labeling of the substance. (2) The known efficacy or usefulness of the substance for the marketed, advertised or labeled purpose. (3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold. (4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance. (5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means. (c) Limitation For purposes of this section, evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption. .